BR100 Increased By (0.54%)
BR30 Increased By (0.7%)
KSE100 Increased By (0.58%)
KSE30 Increased By (0.63%)
AGHA 6.43 Increased By ▲ 0.05 (0.78%)
BECO 4.38 Increased By ▲ 0.03 (0.69%)
BML 63.50 Increased By ▲ 0.95 (1.52%)
BOP 31.52 Increased By ▲ 0.13 (0.41%)
CNERGY 11.86 Increased By ▲ 0.13 (1.11%)
CSIL 5.99 Increased By ▲ 0.08 (1.35%)
FCCL 61.90 Increased By ▲ 0.19 (0.31%)
FFL 14.86 Increased By ▲ 0.07 (0.47%)
FNEL 1.30 Increased By ▲ 0.06 (4.84%)
KEL 6.38 Increased By ▲ 0.06 (0.95%)
KOSM 5.94 Increased By ▲ 0.04 (0.68%)
LOTCHEM 24.68 Decreased By ▼ -0.01 (-0.04%)
MLCF 104.50 Increased By ▲ 0.57 (0.55%)
NBP 174.85 Increased By ▲ 1.53 (0.88%)
NCPL 51.60 Decreased By ▼ -0.23 (-0.44%)
NPL 54.50 Increased By ▲ 0.47 (0.87%)
OGDC 318.00 Increased By ▲ 2.13 (0.67%)
PACE 9.40 Increased By ▲ 0.14 (1.51%)
PAEL 35.68 Increased By ▲ 0.10 (0.28%)
PIBTL 13.90 Increased By ▲ 0.24 (1.76%)
PPL 227.10 Increased By ▲ 1.03 (0.46%)
PRL 81.26 Increased By ▲ 0.98 (1.22%)
PTC 47.24 Increased By ▲ 0.60 (1.29%)
SSGC 24.00 Increased By ▲ 0.18 (0.76%)
TBL 9.37 Increased By ▲ 0.13 (1.41%)
TELE 7.64 Increased By ▲ 0.09 (1.19%)
TPL 24.87 Increased By ▲ 0.33 (1.34%)
TPLP 13.19 Increased By ▲ 0.20 (1.54%)
TREET 26.15 Increased By ▲ 0.17 (0.65%)
TRG 53.80 Increased By ▲ 0.47 (0.88%)
World

Novartis agrees to acquire Anthos for up to $3.1 billion

Published Updated
By

Swiss pharmaceutical giant Novartis said on Tuesday it has agreed to acquire biopharma firm Anthos Therapeutics for up to $3.1 billion.

Anthos was founded by Blackstone Life Sciences and Novartis in 2019 to develop, manufacture, and commercialize abelacimab, a treatment to prevent stroke and the recurrence of blood clots.

The transaction, expected to close in the first half of this year, will cost Novartis $925 million upfront with potential additional payment of up to $2.15 billion, the company said.

Novartis raises annual sales guidance until 2028

“With its deep roots in the cardiovascular space, Novartis is especially well positioned to advance abelacimab’s clinical development and bring this innovative product to healthcare providers and patients,” said Bill Meury, CEO at Anthos.

Reuters reported in December 2023 that Blackstone was exploring the sale of Anthos.

Comments

Comments are closed for this article.